629 related articles for article (PubMed ID: 27298019)
1. Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.
Wells JM; Farris RF; Gosdin TA; Dransfield MT; Wood ME; Bell SC; Rowe SM
Lancet Respir Med; 2016 Aug; 4(8):636-645. PubMed ID: 27298019
[TBL] [Abstract][Full Text] [Related]
2. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Artery Enlargement Is Associated With Cardiac Injury During Severe Exacerbations of COPD.
Wells JM; Morrison JB; Bhatt SP; Nath H; Dransfield MT
Chest; 2016 May; 149(5):1197-204. PubMed ID: 26501747
[TBL] [Abstract][Full Text] [Related]
4. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Kerem E; Konstan MW; De Boeck K; Accurso FJ; Sermet-Gaudelus I; Wilschanski M; Elborn JS; Melotti P; Bronsveld I; Fajac I; Malfroot A; Rosenbluth DB; Walker PA; McColley SA; Knoop C; Quattrucci S; Rietschel E; Zeitlin PL; Barth J; Elfring GL; Welch EM; Branstrom A; Spiegel RJ; Peltz SW; Ajayi T; Rowe SM;
Lancet Respir Med; 2014 Jul; 2(7):539-47. PubMed ID: 24836205
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.
Wolter DJ; Onchiri FM; Emerson J; Precit MR; Lee M; McNamara S; Nay L; Blackledge M; Uluer A; Orenstein DM; Mann M; Hoover W; Gibson RL; Burns JL; Hoffman LR;
Lancet Respir Med; 2019 Dec; 7(12):1027-1038. PubMed ID: 31727592
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary arterial enlargement and acute exacerbations of COPD.
Wells JM; Washko GR; Han MK; Abbas N; Nath H; Mamary AJ; Regan E; Bailey WC; Martinez FJ; Westfall E; Beaty TH; Curran-Everett D; Curtis JL; Hokanson JE; Lynch DA; Make BJ; Crapo JD; Silverman EK; Bowler RP; Dransfield MT; ;
N Engl J Med; 2012 Sep; 367(10):913-21. PubMed ID: 22938715
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of the 6-minute walk test as a screening test for pulmonary arterial enlargement in COPD.
Oki Y; Kaneko M; Fujimoto Y; Sakai H; Misu S; Mitani Y; Yamaguchi T; Yasuda H; Ishikawa A
Int J Chron Obstruct Pulmon Dis; 2016; 11():2869-2875. PubMed ID: 27920514
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis: A cohort study.
Zouk AN; Gulati S; Xing D; Wille KM; Rowe SM; Wells JM
PLoS One; 2020; 15(2):e0229173. PubMed ID: 32078644
[TBL] [Abstract][Full Text] [Related]
10. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD
Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
12. Estimated Ventricular Size, Asthma Severity, and Exacerbations: The Severe Asthma Research Program III Cohort.
Ash SY; Sanchez-Ferrero GV; Schiebler ML; Rahaghi FN; Rai A; Come CE; Ross JC; Colon AG; Cardet JC; Bleecker ER; Castro M; Fahy JV; Fain SB; Gaston BM; Hoffman EA; Jarjour NN; Lempel JK; Mauger DT; Tattersall MC; Wenzel SE; Levy BD; Washko GR; Israel E; San Jose Estepar R;
Chest; 2020 Feb; 157(2):258-267. PubMed ID: 31521672
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
[TBL] [Abstract][Full Text] [Related]
14. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.
Han MK; Quibrera PM; Carretta EE; Barr RG; Bleecker ER; Bowler RP; Cooper CB; Comellas A; Couper DJ; Curtis JL; Criner G; Dransfield MT; Hansel NN; Hoffman EA; Kanner RE; Krishnan JA; Martinez CH; Pirozzi CB; O'Neal WK; Rennard S; Tashkin DP; Wedzicha JA; Woodruff P; Paine R; Martinez FJ;
Lancet Respir Med; 2017 Aug; 5(8):619-626. PubMed ID: 28668356
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary artery enlargement predicts poor outcome during acute exacerbations of fibrotic interstitial lung disease.
Kogo M; Otsuka K; Morimoto T; Nagata K; Nakagawa A; Tomii K
Respirology; 2019 Aug; 24(8):777-782. PubMed ID: 30866125
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
[TBL] [Abstract][Full Text] [Related]
17. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV
Ramos KJ; Quon BS; Heltshe SL; Mayer-Hamblett N; Lease ED; Aitken ML; Weiss NS; Goss CH
Chest; 2017 Jun; 151(6):1320-1328. PubMed ID: 28115168
[TBL] [Abstract][Full Text] [Related]
19. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study.
Chaudhary MFA; Hoffman EA; Guo J; Comellas AP; Newell JD; Nagpal P; Fortis S; Christensen GE; Gerard SE; Pan Y; Wang D; Abtin F; Barjaktarevic IZ; Barr RG; Bhatt SP; Bodduluri S; Cooper CB; Gravens-Mueller L; Han MK; Kazerooni EA; Martinez FJ; Menchaca MG; Ortega VE; Iii RP; Schroeder JD; Woodruff PG; Reinhardt JM
Lancet Digit Health; 2023 Feb; 5(2):e83-e92. PubMed ID: 36707189
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function.
Katz JB; Shah P; Trillo CA; Alshaer MH; Peloquin C; Lascano J
Respir Med; 2023 Jun; 212():107237. PubMed ID: 37030586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
